This clinical trial studies the treatment of metastatic castration-resistant prostate cancer using ifinatamab deruxtecan, either alone or in combination with other medications. The study aims to evaluate whether this treatment is safe and effective for patients whose cancer has continued to progress despite previous hormone therapy treatments.
The main treatment being tested is ifinatamab deruxtecan, which is given through an intravenous infusion. Some patients may also receive other medications including docetaxel, abiraterone, or enzalutamide. The study will monitor how well patients respond to treatment by measuring changes in tumor size and levels of a protein called prostate-specific antigen in the blood.
During the study, doctors will track patients’ progress by performing regular medical examinations and tests. They will monitor for side effects and measure how well the treatment works in controlling cancer growth. The study will also look at how long patients live without their cancer getting worse and their overall survival time.
France 
Germany 
Ireland 
Italy 
Poland 
Spain 
The Netherlands